BOTOX injection to treat strabismus after infant botulism type B infection by Bonaffini, Sarah G et al.
Philadelphia College of Osteopathic Medicine 
DigitalCommons@PCOM 
Ophthalmology Resident Research Graduate Medical Education Research 
12-1-2020 
BOTOX injection to treat strabismus after infant botulism type B 
infection 
Sarah G Bonaffini 
Philadelphia College of Osteopathic Medicine 
Victoria Cocozza 
Jing Jin 
Follow this and additional works at: https://digitalcommons.pcom.edu/ophthalmology_residents 
 Part of the Ophthalmology Commons 
Recommended Citation 
Bonaffini, Sarah G; Cocozza, Victoria; and Jin, Jing, "BOTOX injection to treat strabismus after infant 
botulism type B infection" (2020). Ophthalmology Resident Research. 1. 
https://digitalcommons.pcom.edu/ophthalmology_residents/1 
This Article is brought to you for free and open access by the Graduate Medical Education Research at 
DigitalCommons@PCOM. It has been accepted for inclusion in Ophthalmology Resident Research by an authorized 
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu. 
American Journal of Ophthalmology Case Reports 20 (2020) 100895
Available online 28 August 2020
2451-9936/© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
BOTOX injection to treat strabismus after infant botulism type B infection☆ 
Sarah G. Bonaffini a, Victoria Cocozza a, Jing Jin b,* 
a Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA 
b Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA   






A B S T R A C T   
Purpose: The significance of botulinum toxin to ophthalmologists is twofold. Botulism, a medical emergency, 
frequently presents with ocular findings including blurred vision, diplopia, ptosis, and photophobia as a result of 
the neurotoxin produced by Clostridium botulinum. However, botulinum toxins also have therapeutic uses for 
medical conditions including strabismus. The safety and efficacy of Botulinum toxin A in patients with a history 
of botulism has not been reported. 
Observations: We report a 9-week-old infant, diagnosed with type B toxin positive infant botulism treated with 
human botulism immune globulin, who developed a large angle exotropia. The infant was treated with intra-
muscular injections of botulinum toxin A to the extraocular muscles resulting in a favorable initial response but 
ultimately required strabismus surgery. Clinical manifestations and management of botulism are reviewed and 
botulinum toxin in the treatment of pediatric strabismus is discussed. 
Conclusions and importance: This case demonstrates safe administration of onabotulinumtoxinA to an infant with 
a history of antitoxin-treated botulism, resulting in a transient improvement in control of infantile exotropia.   
Case report 
A 9-week-old previously healthy, full-term white female presented 
with a two-week history of increased irritability, constipation, decreased 
feeding, intermittent vomiting, and lethargy. The parents reported that 
her cry became weak and shrill. The patient resided with her parents and 
5-year-old sister in a neighborhood with extensive construction nearby. 
She was initially breast-fed, but transitioned to bottle feedings four 
weeks before presentation. The parents denied canned food and honey 
consumption, and neither parent worked in construction. 
Neurologic examination revealed bilateral reactive but sluggish pu-
pils constricting from 5 to 3 mm, full extraocular movements, and ptosis 
obscuring the corneal reflex. No ocular misalignment was noted. Her 
face was hypomimic, with minimal furrowing of the glabella and min-
imal creasing of the perioral region. Her suck was weak. She was 
diffusely hypotonic and had difficulty holding her head upright on pull- 
to-sit. Deep tendon reflexes were difficult to elicit. She was diagnosed 
with infant botulism, admitted to the intensive care unit, and received 
human botulism immune globulin (BIG-IV, California Department of 
Public Health, Richmond, CA).1 A stool specimen tested positive for 
Clostridium botulinum toxin type B. She was discharged from the hospital 
seven days after admission and continued to receive physical therapy at 
home. An ophthalmologic examination was performed at age 13 weeks, 
three weeks after discharge, during which the patient demonstrated 
central, steady, and maintained fixation with either eye. Additionally, 
no evidence of ocular misalignment was noted. 
At 4 months of age, the child’s pediatrician noticed a “left lazy eye.” 
Repeat ophthalmologic examination showed a greater than 40 prism 
diopter intermittent alternating exotropia for both distance and near. 
Her cycloplegic refraction showed right eye: − 2.00 + 2.00 at 105◦ and 
left eye: − 2.00 + 2.00 at 75◦. Her left eye showed poorer fixation and 
more frequent deviation than the right eye. She was treated with 
patching of the right eye 1–2 hours daily. At 6 months of age, both eyes 
fixated and followed well; however, an intermittent exotropia with poor 
control persisted. The alignment failed to improve after an additional 
two months of patching (Fig. 1A). After discussing treatment options, 
the family elected to proceed with botulinum toxin A injection (BTX-A). 
At 7 months of age, she received transconjunctival, intramuscular in-
jections of onabotulinumtoxinA (Botox, Allergan Inc., Madison, NJ) 
without electromyographic guidance, with 2.5 units to the right lateral 
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rectus muscle and 5 units to the left lateral rectus muscle while under 
general anesthesia. 
One week following the procedure, she displayed a flick exotropia in 
the primary position (Fig. 1B). Three months after the initial injection, 
alignment was adequate under binocular viewing (Fig. 1C); however, 
with cross cover testing she demonstrated a poorly-controlled exophoria 
of 30 prism diopters. The decision was made to again proceed with 
intramuscular injections of onabotulinumtoxinA. At 1 year of age, the 
patient underwent transconjunctival, intramuscular injections of 10 
units onobotulinumtoxinA to the left lateral rectus muscle without 
electromyographic guidance. Her exotropia decreased to 20 prism di-
opters in the first month following injection, and subsequently returned 
to 40 prism diopters three months later. At 16 months of age, she un-
derwent bilateral lateral rectus muscle recession of 10 mm. Seven weeks 
postoperatively, she displayed a 15 prism diopter intermittent exotropia 
by cross cover testing. 
Discussion 
Clostridium botulinum, a gram-positive obligate anaerobic rod 
commonly found in the soil, produces heat-resistant endospores and is 
able to survive under adverse conditions. The bacterium produces a 
neurotoxic protein, botulinum toxin, during sporulation in an anaerobic 
environment. Patients may contract botulism when C. botulinum spores 
enter a wound, grow in intestines, or the toxin may also enter the body 
through contaminated food or injection. There have also been reported 
cases in which iatrogenic botulism has occurred.2 Infant botulism or 
intestinal toxemia botulism is the most common form of human botulism 
in the United States.3 
A total of 182 confirmed cases were reported to the CDC in 2017.4 
Among these, 141 cases (77%) were infant botulism from 26 states and 
the District of Columbia, with California reporting 48 cases (34%). The 
median age of patients was 4 months (range: 0–12 months) and 72 
(51%) were girls. There are four distinct phenotypic C. botulinum groups 
(I-IV), producing seven serotypes (A-G) of botulinum toxin.5 The pre-
dominant toxin types identified in infant botulism were B (n = 88, 62%) 
and A (n = 52, 37%).4 Most cases of infant botulism are thought to be 
caused by acquiring the spores from the natural environment. Patients 
often live near a construction site or an area of soil disturbance.4 
Botulinum toxin selectively blocks neurotransmitter release by pre-
venting fusion of vesicles containing acetylcholine with the presynaptic 
membrane. The upper cranial nerves are affected first, resulting in 
ocular signs due to intraocular and extraocular ophthalmoplegias. Later, 
damage to the lower cranial nerves leads to bulbar signs: paralysis of the 
lips, tongue, pharynx, larynx, and facial muscles. Progression over the 
next 1–3 days due to involvement of motor neurons to the somatic 
muscles results in loss of head control, hypotonia, and constipation. 
Death can result from respiratory failure or as a consequence of 
extended paralysis. Recovery often takes weeks to months.6–8 
Ocular findings in botulism are limited in the ophthalmologic liter-
ature due to ophthalmologists not usually being involved in evaluating 
presenting botulism cases. “Blurred vision” is reported in almost every 
adult patient. Ptosis followed by an abnormal pupillary reaction to light, 
in addition to mydriasis, dominate the most common ophthalmologic 
Fig. 1. Ocular alignment before (A) and after botulinum toxin A injection: (B) 1 week after and (C) 3 months after.  
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abnormalities in infant botulism.9,10 In a report on six-month or longer 
follow-up, the ocular and bulbar symptoms were no longer a major 
complaint and likely resolved.11 
The purpose of treatment for botulism is meticulous supportive care 
with attention to breathing through respiratory support and monitored 
feeding, in addition to prompt administration of human antitoxin in 
order to neutralize the circulating toxin. Antitoxins provide acquired 
passive immunity by neutralizing free toxin before it binds to the re-
ceptor on the presynaptic membrane, thus, early administration is crit-
ical. Two types of antitoxin are available: 1) heptavalent botulism 
antitoxin is derived from equine IgG that can neutralize toxins A through 
G; 2) BIG-IV contains IgG derived from immunized adult donors who 
contributed to the plasma pool specific for toxins A and B.3,12–14 People 
may also gain acquired active immunity to botulinum toxin following 
infection. 
The neuromuscular junction blockade of botulinum toxins provides 
therapeutic uses. Two toxin preparations are commercially available in 
the United States: type-A (onabotulinumtoxinA [Botox®], abobotuli-
numtoxinA [Dysport®], and incobotulinumtoxinA [XEOMIN®]) and 
type-B (rimabotulinumtoxinB [Myobloc®]). Currently, the Food and 
Drug Administration approves both toxins for cervical dystonia; toxin A 
is also approved for strabismus, blepharospasm, hemifacial spasm, and 
glabellar wrinkles.15 BTX-A injection has been a treatment option for 
strabismus for decades.16 In comparison to incisional strabismus sur-
gery, BTX-A treatment is less invasive and offers easier postprocedural 
recovery. Adults may receive injections in outpatient clinics. For chil-
dren, BTX-A treatment has the advantages of less general anesthesia 
time, reduced overcorrections, muscle preservation, and no post pro-
cedure topical medication. For certain types of esotropia, BTX-A injec-
tion has reported success rates comparable to extraocular muscle 
surgeries. The effect is less predictable for exotropia correction.17 
To our knowledge, there are no reported cases of infantile exotropia 
developing two months following recovery from infant botulism, as well 
as a lack of information on BTX-A use in a patient with a history of 
botulism and antitoxin treatment. Our patient had no adverse reactions 
to onabotulinumtoxinA. The first injection was performed five months 
after BIG-IV treatment and resulted in a greater than 30 prism diopter 
exotropia angle reduction and improved alignment control shortly 
following the injection. This suggests sufficient half-life elimination or 
decay of acquired passive immunity. The half-life of infused BIG-IV is 
approximately 28 days.3 Given this half-life, we calculate that at the 
time of onabotulinumtoxinA injection, more than five half-lives had 
passed and the residual antitoxin in our patient would have been less 
than 3% of the administered dose. Additionally, our patient had 
C. botulinum type B illness, and her acquired active immunity may have 
produced antitoxin B antibodies with no effect on toxin A as anti-type B 
antibodies do not cross-neutralize toxin type A. The onabotulinumtox-
inA injections might have been ineffective after toxin A, producing 
C. botulinum infection. Although onabotulinumtoxinA showed only 
short-term effect in this case of exotropia, the injections postponed the 
surgical procedure until after the patient’s first birthday. In conclusion, 
onabotulinumtoxinA is a viable treatment option for infantile exotropia 
in a patient with a history of infant botulism type B treated with human 
antitoxin. 
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